Brooke Daniel

1.2k total citations
17 papers, 196 citations indexed

About

Brooke Daniel is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Brooke Daniel has authored 17 papers receiving a total of 196 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 9 papers in Cancer Research and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Brooke Daniel's work include Cancer Treatment and Pharmacology (11 papers), HER2/EGFR in Cancer Research (9 papers) and Breast Cancer Treatment Studies (6 papers). Brooke Daniel is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), HER2/EGFR in Cancer Research (9 papers) and Breast Cancer Treatment Studies (6 papers). Brooke Daniel collaborates with scholars based in United States, United Kingdom and Portugal. Brooke Daniel's co-authors include Denise A. Yardley, John D. Hainsworth, Cassie M. Lane, Janice F. Eakle, Patrick J. Ward, Sara M. Tolaney, Foluso O. Ademuyiwa, Lisa A. Carey, Adam Brufsky and Howard A. Burris and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Breast Cancer Research and Treatment.

In The Last Decade

Brooke Daniel

17 papers receiving 192 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brooke Daniel United States 7 170 69 58 33 31 17 196
Tetsuhiro Yoshinami Japan 6 116 0.7× 53 0.8× 50 0.9× 18 0.5× 33 1.1× 48 174
Jason Mouabbi United States 7 113 0.7× 64 0.9× 100 1.7× 51 1.5× 24 0.8× 41 205
Marcelle Goldner Cesca Brazil 6 223 1.3× 76 1.1× 99 1.7× 88 2.7× 27 0.9× 18 272
Giuliano Santos Borges Brazil 7 138 0.8× 97 1.4× 33 0.6× 36 1.1× 22 0.7× 16 183
Hiroji Iwata Japan 8 192 1.1× 122 1.8× 43 0.7× 63 1.9× 37 1.2× 26 238
Kaisa Sunela Finland 11 93 0.5× 112 1.6× 68 1.2× 17 0.5× 71 2.3× 29 220
Míriam Arumí Spain 5 113 0.7× 80 1.2× 47 0.8× 37 1.1× 33 1.1× 13 172
Donata Sartori Italy 6 72 0.4× 36 0.5× 51 0.9× 13 0.4× 22 0.7× 18 126
A. Stopeck United States 9 242 1.4× 80 1.2× 90 1.6× 56 1.7× 68 2.2× 20 295
Katia Ventura United States 6 104 0.6× 24 0.3× 63 1.1× 33 1.0× 19 0.6× 9 139

Countries citing papers authored by Brooke Daniel

Since Specialization
Citations

This map shows the geographic impact of Brooke Daniel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brooke Daniel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brooke Daniel more than expected).

Fields of papers citing papers by Brooke Daniel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brooke Daniel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brooke Daniel. The network helps show where Brooke Daniel may publish in the future.

Co-authorship network of co-authors of Brooke Daniel

This figure shows the co-authorship network connecting the top 25 collaborators of Brooke Daniel. A scholar is included among the top collaborators of Brooke Daniel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brooke Daniel. Brooke Daniel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
Daniel, Brooke, et al.. (2023). Advancing the Care of Women With HER2-Positive Metastatic Breast Cancer. Journal of the Advanced Practitioner in Oncology. 14(3). 248–251. 1 indexed citations
3.
Damodaran, Senthil, Nisha Unni, Karthik V. Giridhar, et al.. (2022). Abstract P1-18-35: Futibatinib in combination with fulvestrant in patients with metastatic breast cancer (MBC) harboring high-level FGFR1 amplification: Preliminary data from a phase 2 study. Cancer Research. 82(4_Supplement). P1–18. 3 indexed citations
4.
Dièras, Véronique, Robert Weaver, Sara M. Tolaney, et al.. (2021). Abstract PD13-07: Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer. Cancer Research. 81(4_Supplement). PD13–7. 47 indexed citations
5.
Garrido-Castro, Ana C., Tanya E. Keenan, Tianyu Li, et al.. (2021). Saci-IO TNBC: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1– metastatic triple-negative breast cancer (mTNBC).. Journal of Clinical Oncology. 39(15_suppl). TPS1106–TPS1106. 18 indexed citations
6.
Yardley, Denise A., N. W. Peacock, Brooke Daniel, et al.. (2020). Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy. Breast Cancer Research and Treatment. 180(3). 647–655. 5 indexed citations
7.
Yardley, Denise A., Patrick J. Ward, Brooke Daniel, et al.. (2016). Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial. Clinical Breast Cancer. 16(5). 349–355. 33 indexed citations
8.
Yardley, Denise A., James A. Reeves, Elizabeth Claire Dees, et al.. (2016). Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study. Clinical Breast Cancer. 16(6). 471–479.e1. 29 indexed citations
9.
10.
Yardley, Denise A., Linda D. Bosserman, Mark Keaton, et al.. (2015). TITAN: Phase III study of doxorubicin/cyclophosphamide (AC) followed by ixabepilone (Ixa) or paclitaxel (Pac) in early-stage, triple-negative breast cancer (TNBC).. Journal of Clinical Oncology. 33(15_suppl). 1000–1000. 5 indexed citations
11.
Yardley, Denise A., Michelle Melisko, Andres Forero, et al.. (2015). METRIC: A randomized international study of the antibody-drug conjugate glembatumumab vedotin (GV or CDX-011) in patients (pts) with metastatic gpNMB-overexpressing triple-negative breast cancer (TNBC).. Journal of Clinical Oncology. 33(15_suppl). TPS1110–TPS1110. 9 indexed citations
12.
Yardley, Denise A., et al.. (2014). Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Operable Breast Cancer: A Phase II Trial of the Sarah Cannon Research Institute. Clinical Breast Cancer. 15(4). 251–258. 4 indexed citations
13.
Yardley, Denise A., Lowell L. Hart, David Waterhouse, et al.. (2013). Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer. Breast Cancer Research and Treatment. 142(3). 655–665. 6 indexed citations
14.
Yardley, Denise A., Zeqiang Ma, Patrick J. Ward, et al.. (2013). Abstract 2397: Correlation between biomarker status and response to EGFR inhibition in triple-negative breast cancer (TNBC): findings from a Phase II trial.. Cancer Research. 73(8_Supplement). 2397–2397. 1 indexed citations
15.
Yardley, Denise A., Cynthia R. Osborne, Paul Richards, et al.. (2012). Interim safety results of eribulin (E) combined with ramucirumab (RAM) in patients (pts) with advanced metastatic breast cancer (MBC).. Journal of Clinical Oncology. 30(27_suppl). 110–110. 1 indexed citations
16.
Yardley, Denise A., Brooke Daniel, Roger Inhorn, et al.. (2010). A Phase II Trial of Dose-Dense Neoadjuvant Gemcitabine, Epirubicin, and Albumin-Bound Paclitaxel With Pegfilgrastim in the Treatment of Patients With Locally Advanced Breast Cancer. Clinical Breast Cancer. 10(5). 367–372. 17 indexed citations
17.
Daniel, Brooke & Kimberly Blackwell. (2005). Ectopic breast cancer: rare, treatable, and potentially curable. Community Oncology. 2(2). 120–122. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tetsuhiro Yoshinami Breakdown of academic impact, for papers by Jason Mouabbi Breakdown of academic impact, for papers by Marcelle Goldner Cesca Breakdown of academic impact, for papers by Giuliano Santos Borges Breakdown of academic impact, for papers by Hiroji Iwata Breakdown of academic impact, for papers by Kaisa Sunela Breakdown of academic impact, for papers by Míriam Arumí Breakdown of academic impact, for papers by Donata Sartori Breakdown of academic impact, for papers by A. Stopeck Breakdown of academic impact, for papers by Katia Ventura
Rankless by CCL
2026